

LISTING OF THE CLAIMS

The following listing of the claims replaces all previous listings.

Claims 1-10 (**cancelled**)

11. (**previously presented**) A modified monovalent antibody fragment comprising a heavy chain and a light chain, wherein:

said heavy chain consists of a V_H domain covalently linked at its C-terminus to a C_{H1} domain;

said light chain consists of a V_L domain, which is complementary to the V_H domain, covalently linked at its C-terminus to a C_L domain;

said C_{H1} domain is extended to provide a hinge domain which contains only one cysteine residue;

the cysteine residues in the V_H , C_{H1} , V_L and C_L domains are in disulphide linkage to each other; and

the cysteine residue in the hinge domain is covalently linked through its sulphur atom to a polymer molecule, wherein said polymer molecule has an average molecular weight of from about 25,000 Da to about 40,000 Da.

12. (**previously presented**) An antibody fragment according to claim 11 wherein the polymer is an optionally substituted, straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymer, or a branched or unbranched polysaccharide, said polymer being optionally substituted with hydroxy, methyl, or methoxy groups.

13. (**previously presented**) An antibody fragment according to claim 12 wherein the polymer is an optionally substituted, straight or branched chain poly(ethylene glycol), poly(propylene glycol) or poly(vinyl alcohol) or a derivative thereof reactive for linking the antibody fragment and polymer, said polymer being optionally substituted with hydroxy, methyl, or methoxy groups.

14. **(previously presented)** An antibody fragment according to claim 13 wherein the polymer is methoxy(polyethylene glycol), or a derivative thereof reactive for linking the antibody fragment and polymer.
15. **(previously presented)** An antibody fragment according to claim 11 covalently attached to one or more effector or reporter molecules.
16. **(previously presented)** A pharmaceutical composition comprising a monovalent antibody fragment according to any one of the preceding claims together with one or more pharmaceutically acceptable excipients, diluents or carriers.